Report of gene-edited human embryos sparks worries about the technology’s future uses

A preprint study led by Columbia University researcher Dieter Egli used base editing to modify genes in human embryos, raising ethical concerns about the potential for gene editing to be used for non-therapeutic enhancements. Scientists warn the work, though not yet peer-reviewed, contributes to debates on embryo editing risks and benefits, despite lacking clear medical application or clinical readiness." "article": "Researchers at Columbia University, led by cell biology expert Dieter Egli, have published a preprint detailing the use of base editing—a CRISPR-derived technique—to modify two genes (*PCSK9* and *HBG1/HBG2*) in human zygotes, or single-cell embryos. The edits targeted genes linked to cholesterol regulation and fetal hemoglobin production, chosen for their scientific relevance rather than therapeutic necessity. The study, not yet peer-reviewed, acknowledges its role in sparking discussions about embryo editing but emphasizes that clinical translation remains premature. Scientists express concern that the U.S. may be moving toward broader acceptance of gene editing for non-medical purposes, such as parental preference enhancements. Alexis Komor of the University of California, San Diego, noted the research signals a shift in societal tolerance, while Krishanu Saha of the University of Wisconsin–Madison criticized the lack of a pathogenic mutation to justify the edits. Saha dismissed the work as a clinical breakthrough, stating it does not demonstrate genome-wide safety or medical viability. Egli defended the study as foundational research, arguing that expanding scientific knowledge often leads to future medical advancements. The work builds on CRISPR’s 2012 discovery, which raised ethical questions about embryonic editing for disease treatment or enhancement. In 2020, an international commission outlined conditions for acceptable human germline editing, but no formal moratorium exists on embryo research. The study contrasts with the 2018 controversy surrounding Chinese researcher He Jiankui, who edited embryos resulting in live births—a violation of medical ethics that led to his imprisonment. While Egli’s research did not implant embryos, critics argue it blurs ethical boundaries by normalizing non-therapeutic genetic modifications. The preprint’s publication on bioRxiv underscores growing tensions between scientific progress and ethical oversight in gene-editing applications.